問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Linkou Chang Gung Medical Foundation

Division of Rheumatology

List

94Cases

2022-01-01 - 2023-11-22

Phase II

A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)

  • Condition/Disease

    Primary Sjogren's Syndrome

  • Test Drug

    Nipocalimab Solution for Intravenous Infusion

Participate Sites
2Sites

Recruiting2Sites

2022-01-01 - 2025-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2021-07-09 - 2026-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-07-01 - 2027-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting2Sites

2017-04-01 - 2019-10-31

Phase II

A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus

  • Condition/Disease

    Systemic Lupus Erythematosus (SLE)

  • Test Drug

    GDC-0853

Participate Sites
8Sites

Terminated6Sites

郭昶甫
Linkou Chang Gung Medical Foundation

Division of Rheumatology

2017-01-01 - 2020-10-31

Phase III

A Multicenter, Open-label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis

  • Condition/Disease

    Rheumatoid Arthritis

  • Test Drug

    Olokizumab

Participate Sites
5Sites

Recruiting2Sites

Terminated1Sites

Study ended1Sites

2017-01-01 - 2019-11-30

Phase II

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations

  • Condition/Disease

    1. Systemic Lupus Erythematosus and Active Skin Manifestations2. Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations

  • Test Drug

    BIIB059

Participate Sites
4Sites

Recruiting4Sites

方耀凡
Linkou Chang Gung Medical Foundation

Division of Rheumatology

2016-09-01 - 2019-01-31

Phase III

A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy

  • Condition/Disease

    Rheumatoid Arthritis

  • Test Drug

    Olokizumab

Participate Sites
5Sites

Terminated3Sites

Study ended1Sites

黃春明
China Medical University Hospital

2013-04-01 - 2022-12-05

Phase IV

A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, AutoantibodyPositive Systemic Lupus Erythematosus Receiving Belimumab

  • Condition/Disease

    Systemic Lupus Erythematosus

  • Test Drug

    BENLYSTA (Belimumab)

Participate Sites
8Sites

Recruiting1Sites

Terminated7Sites

黃春明
China Medical University Hospital

2008-08-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

1 6 7 8 9 10
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB